Clinical Trial Results


pharma-topgainers-041918.jpg The following are some of today's top gainers in the pharma/biotech sector.

GlaxoSmithKline plc (GSK, GSK.L) and Innoviva, Inc. (INVA) announced Thursday that the landmark IMPACT study published in the New England Journal of Medicine or NEJM showed significant benefits of Trelegy Ellipta for patients with chronic obstructive pulmonary disease or COPD. The once-daily single...

pharma-041618.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-up1-041718.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmadown-041618.jpg Celldex Therapeutics plunged 64% on Monday, following disappointing results from its phase IIb study of Glembatumumab vedotin in patients with metastatic triple negative breast cancers, dubbed METRIC.

pharmaup-041618.jpg Apellis Pharma gained more than 12%, boosted by interim data from its ongoing phase Ib trial evaluating APL-2 in subcutaneous formulation as a monotherapy in paroxysmal nocturnal hemoglobinuria, dubbed PADDOCK.

april12-up-041218.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-041118.jpg CymaBay gained more than 11% on Wednesday, following positive new 12-week and 26-week results from its ongoing phase II study of Seladelpar in patients with primary biliary cholangitis.

april-up-041018.jpg Spectrum Pharmaceuticals gained nearly 42% on Tuesday, following an update on its phase II study of Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer, being conducted at MD Anderson Cancer Center.

pharma-040518.jpg AveXis Inc. (AVXS) gained more than 80% on Monday, as the Company is all set to be acquired by Novartis (NVS) for $218 per share or a total approximate value of $8.7 billion.

Ionis Pharmaceuticals, Inc. (IONS) announced Monday it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to biopharmaceutical company AstraZeneca (AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis...

Incyte Corp. (INCY) and Merck (MRK) said that an external Data Monitoring Committee or eDMC review of the pivotal Phase 3 ECHO-301/KEYNOTE-252 study results evaluating Incyte's epacadostat in combination with Merck's KEYTRUDA in patients with unresectable or metastatic melanoma determined that the study...

pharmacy-040318.jpg Tenax Therapeutics gained over 47% on Wednesday after it announced that it had a productive pre-Investigational New Drug (pre-IND) meeting with the FDA for a phase II study of Levosimendan in Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

Novartis (NVS) announced that JAMA Cardiology has published results from a post-hoc analysis demonstrating that treatment with Entresto (sacubitril/valsartan) significantly improved seven out of 10 types of physical and social activities at eight months in heart failure patients with reduced ejection...

april03-down-040418.jpg The following are some of the stocks that lost the largest percentage in price today in the pharma/biotech sector.

Follow RTT